Akba stock price is benefiting from stable biotech

Akba stock price is benefiting from stable biotech sector funding flows. Investor sentiment indexes have shifted to “greed” from “neutral,” often a bullish short-term indicator. Akebia Therapeutics, Inc. price-consensus-chart | Akebia Therapeutics, Inc. Quote Akebia Therapeutics (Nasdaq: AKBA) has announced the pricing of its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share . The offering is expected to generate gross proceeds of $50.0 million before deducting underwriting costs and other expenses. Short-term forecasts for akba stock price remain positive, especially with Bollinger Bands tightening — often a setup for rapid price expansion. Traders should watch $1.65 as a near-term breakout level.